23
Participants
Start Date
November 19, 2012
Primary Completion Date
July 30, 2016
Study Completion Date
December 26, 2018
dabrafenib
Given PO
pazopanib hydrochloride
Given PO
Correlative studies
"Pharmacokinetic studies:~Blood draw for various time points:~Cycle 1 Days 1, 2, 3, 4 and 15; Cycle 2 Days 1, 2; and day 1 of Cycles 4, 6 and 12~* Pharmacogenomic studies: Blood draw on Cycle 1 Day 1~* Tumor genotyping: Archival tumor blocks or unstained slides~* BRAF mutation quantification in circulating plasma DNA: Blood draw on Cycles 1-7 Day 1 and every other cycle thereafter; and at time of progression"
Ohio State University Medical Center, Columbus
University of Texas M.D. Anderson Cancer Center, Houston
National Comprehensive Cancer Network
NETWORK
Manisha Shah
OTHER